Trevena (NASDAQ:TRVN) Now Covered by Analysts at StockNews.com

StockNews.com assumed coverage on shares of Trevena (NASDAQ:TRVN) in a report published on Tuesday. The firm issued a sell rating on the biopharmaceutical company’s stock.

Separately, HC Wainwright reiterated a buy rating and set a $9.00 target price on shares of Trevena in a report on Tuesday, April 2nd.

Trevena Price Performance

TRVN stock opened at $0.41 on Tuesday. The business’s fifty day moving average price is $0.46 and its 200 day moving average price is $0.57. Trevena has a 12-month low of $0.30 and a 12-month high of $3.28. The company has a current ratio of 4.66, a quick ratio of 4.66 and a debt-to-equity ratio of 8.35. The company has a market capitalization of $7.56 million, a PE ratio of -0.13 and a beta of 1.11.

Trevena (NASDAQ:TRVN) last released its earnings results on Monday, April 1st. The biopharmaceutical company reported ($1.06) earnings per share for the quarter. The business had revenue of ($0.08) million during the quarter, compared to the consensus estimate of $0.09 million. On average, sell-side analysts anticipate that Trevena will post -1.28 EPS for the current year.

Institutional Investors Weigh In On Trevena

A hedge fund recently bought a new stake in Trevena stock. Jump Financial LLC purchased a new position in Trevena, Inc. (NASDAQ:TRVN) in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 44,396 shares of the biopharmaceutical company’s stock, valued at approximately $27,000. Jump Financial LLC owned about 0.32% of Trevena as of its most recent SEC filing. 13.56% of the stock is owned by hedge funds and other institutional investors.

Trevena Company Profile

Trevena, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain.